Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

NCT01182207 | Completed Phase 1 Results

• 1 other identifier: R06-0632
• Study Type: interventional
• Target: 33
• Locations: 1 country
• Sites: 1

Brief Summary

This study was designed to compare the relative bioavailability (rate and extent of absorption) of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets with that of YAZ® Tablets (by Berlex, Inc.) following a single, oral dose (2 x 3 mg/0.02 mg tablets) in healthy, adult subjects under non-fasting conditions.

Conditions

Healthy

Keywords

Bioequivalence; Healthy Subjects

Outcome Measures

Primary Outcomes (6)

• Cmax of Drospirenone(Maximum Observed Concentration of Drug Substance in Plasma)

  Bioequivalence based on Drospirenone Cmax.

  Blood samples collected over a 120 hour period.

• AUC0-t of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

  Bioequivalence based on Drospirenone AUC0-t.

  Blood samples collected over a 120 hour period.

• AUC0-inf of Drospirenone(Area Under the Concentration-time Curve From Time Zero to Infinity)

  Bioequivalence based on Drospirenone AUC0-inf.

  Blood samples collected over a 120 hour period.

• Cmax of Ethinyl Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)

  Bioequivalence based on Ethinyl Estradiol Cmax.

  Blood samples collected over a 72 hour period.

• AUC0-t of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

  Bioequivalence based on Ethinyl Estradiol AUC0-t.

  Blood samples collected over a 72 hour period.

• AUC0-inf of Ethinyl Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)

  Bioequivalence based on Ethinyl Estradiol AUC0-inf.

  Blood samples collected over a 72 hour period.

Study Arms (2)

Investigational Test Product

EXPERIMENTAL

Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg

Drug: Drospirenone/Ethinyl Estradiol (Gianvi®)

Reference Listed Drug

ACTIVE COMPARATOR

YAZ® Tablets, 3 mg/0.02 mg

Drug: YAZ®

Interventions

Drospirenone/Ethinyl Estradiol (Gianvi®) DRUG

3 mg/0.02 mg Tablets

Also known as: Gianvi®

Investigational Test Product

YAZ® DRUG

3 mg/0.02 mg Tablets

Also known as: Drospirenone/Ethinyl Estradiol (generic name)

Reference Listed Drug

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects who were informed of the nature of the study and agreed to read, review, and sign the informed consent document prior to Period I dosing.
• Subjects who completed the screening process within 28 days prior to Period I dosing.
• Subjects who were healthy, adult, menstruating women 18 to 35 years of age, inclusive, at the time of dosing.
• Subjects with a body mass index (BMI) between 19 and 30 kg/m2, inclusive, and weighed at least 110 pounds.
• Subjects who were healthy as documented by the medical history, physical examination, vital sign assessments, 12-lead electrocardiogram, clinical laboratory assessments, and by general observations. The physical examination also included a gynecological exam. If the subject had completed an acceptable Pap smear and gynecological exam in the previous 12 months (prior to study Day 1) and the documentation of acceptable results were provided, both were deferred. Any abnormalities/deviations from thee normal range which were considered clinically relevant by the study physician and investigator were evaluated for individual cases, documented in study files, and agreed upon by the study physician and investigator prior to enrolling a volunteer in the study and for continued enrollment.
• Female subjects who practice an acceptable non-hormonal method of birth control as judged by the investigator(s) at least 14 days prior to Period I dosing, throughout the study, and until 14 days after Period II dosing. The acceptable non-hormonal birth control methods included: double barriers, non-hormone releasing intrauterine device in place for at least 30 days prior to dosing, abstinence throughout the duration of the study, or surgically sterile for at least 6 months prior to Period I dosing.

You may not qualify if:

• Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
• Volunteers who reported taking any oral contraceptives including estrogen and progestin combined pills and progestin only pills or patch within 28 days prior to Period I dosing, or using injectable contraceptives within 6 months of Period I dosing.
• Volunteers who have ever had progestational hormone implants.
• Volunteers who reported any presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, liver, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s), or psychiatric or epilepsy disease as determined by the clinical investigator(s).
• Volunteers who reported any presence or history of migraines or severe headaches.
• Volunteers who had a systolic blood pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 45 or over 90 mmHg were excluded from the study.
• Volunteers who had a history of thrombotic disorders, have ever had a cerebrovascular accident, or had transient ischemic attacks.
• Volunteers with a history of breast cancer or undiagnosed breast nodules, active malignancies, or undiagnosed vaginal bleeding.
• Volunteers having other conditions that may be aggravated by fluid retention (as determined by principle investigator).
• Volunteers who had a history of jaundice with previous use of oral contraceptives or any other kinds of hormonal contraceptives.
• Volunteers whose clinical laboratory test values outside the acceptable range and when confirmed on re-examination were deemed to be clinically significant.
• Volunteers who demonstrated a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
• Volunteers who reported a history of allergic response(s) to drospirenone/ethinyl estradiol, progestin/estrogens, or related drugs.
• Volunteers who reported the use of any systemic prescription medications in the 14 days prior to Period 1 dosing (with the exception of hormonal contraceptives).
• Volunteers who reported the use of any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.

Sponsors & Collaborators

• Teva Pharmaceuticals USA: lead

Study Sites (1)

PRACS Institute, Ltd.

Fargo, North Dakota, 58104, United States

Location

MeSH Terms

Interventions

drospirenone; Ethinyl Estradiol; drospirenone and ethinyl estradiol combination

Intervention Hierarchy (Ancestors)

Norpregnatrienes; Norpregnanes; Norsteroids; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Estrogenic Steroids, Alkylated; Estradiol Congeners; Gonadal Steroid Hormones; Gonadal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Results Point of Contact

• Title: Associate Director, Biopharmaceutics
• Organization: TEVA Pharmaceuticals, USA

clinicaltrialqueries@tevausa.com

1-866-384-5525

Study Officials

• Anthony R Godfrey, Pharm.D.

  PRACS Institute, Ltd.

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: August 12, 2010
• First Posted: August 16, 2010
• Study Start: July 1, 2006
• Primary Completion: August 1, 2006
• Study Completion: August 1, 2006
• Last Updated: December 8, 2010
• Results First Posted: October 7, 2010

Record last verified: 2010-11

Locations

US (1)